Bayer’s dual neurokinin 1 and 3 receptor antagonist elinzanetant (Lynkuet) reduced the frequency and severity of menopausal vasomotor symptoms in phase 3 OASIS trials, providing a once daily, nonhormonal treatment option for moderate to severe hot flashes.
A recent study shows that even 3.4 minutes of vigorous intermittent lifestyle physical activity per day could significantly reduce cardiovascular risk, particularly in non-exercising women.
Recent study links tibolone use in menopausal hormone therapy to a 52% increased cardiovascular disease risk, emphasizing the need for tailored hormone therapy approaches and further research in BMJ.